Sunday, June 19, 2016
Regular readers perhaps growing bored of hearing me sing the praises of the work being done by the The Brookings Institution on the legal, political and social realities surrounding modern marijuana reform. But two great new Brookings papers (along with this live event about the papers) ensures that I will be continuing to talk about the must-read materials the folks there are continuing to produce. Here are links to the two papers and the summaries provided by Brookings:
Worry about bad marijuana — not Big Marijuana by John Hudak and Jonathan Rauch
Many critics and proponents of marijuana legalization alike have voiced concerns about the potential emergence of Big Marijuana, a corporate lobby akin to Big Tobacco that recklessly pursues profits and wields sufficient clout to shape regulation to its liking.
Although marijuana remains illegal under federal law, medical and/or recreational marijuana is now legal in more than two dozen states. As the federal government has largely tolerated state legalization, corporate capital and muscle have begun moving in on these new state markets. Such commercialization raises a new set of concerns about how industry dynamics may impact consumer behavior and potentially incur social costs.
In their new paper, “Worry about bad marijuana—not Big Marijuana,” John Hudak and Jonathan Rauch argue against alarmism. In analyzing the likely implications of the corporatization of marijuana, they conclude the following:
The marijuana industry will remain a diverse one even as large corporations emerge. The Big Marijuana rubric is more misleading than helpful as a guide to policy because it oversimplifies and stereotypes what is in reality a continuum of business scales and structures.
The marijuana industry is very unlikely to transform into something that looks like Big Tobacco during its notorious heyday. It is more likely that a commercial and regulatory model would look like the one governing alcohol, which is regulated primarily at the state level, combines mandatory with voluntary measures to police industry conduct, does a credible job of preventing antisocial and abusive commercial behavior, and has proven stable over time and broadly acceptable to the public and the industry.
Intelligently regulated and managed, Big Marijuana can be part of the solution. Corporatization, though not without its hazards, has considerable upsides. It brings advantages in terms of public accountability and regulatory compliance, product safety and reliability, market stability, and business professionalism.
Policy should concern itself with harmful practices, not with industry structure, and it should begin with a presumption of neutrality on issues of corporate size and market structure. Attempts to block corporatization are likely to backfire or fail. For policymakers, the concern should be bad marijuana, not big marijuana.
Bootleggers, Baptists, bureaucrats, and bongs: How special interests will shape marijuana legalization by Jonathan Rauch and Philip Wallach
Where there are markets, regulations, and money, special interests and self-serving behavior will not be far away. So argue Philip Wallach and Jonathan Rauch in this new paper that examines how special interests are likely to shape marijuana legalization and regulation in the United States.
Why did legalization of marijuana break through in the face of what had long been overwhelming interest-group resistance? In a post-disruption world, how might key social and bureaucratic actors reorganize and reassert themselves? As legalization ushers in a “new normal” of marijuana-related regulation and lobbying, what kinds of pitfalls and opportunities lie ahead? In this paper, Wallach and Rauch address those questions through the prism of what political economists often call the theory of public choice—the study of how interest groups and bureaucratic incentives influence policy outcomes. Their conclusions include:
For many years, the marijuana-policy debate was dominated by an “iron triangle” of anti-legalization interests: moralists and public-health advocates who believe marijuana use is wrong or harmful; commercial and gray-market interests with stakes in drug treatment and medical marijuana; and law-enforcement and quasi-governmental entities whose budgets and missions are sustained by the war on drugs. Those interests’ combined firepower stunted change even as public support for marijuana prohibition softened.
To make possible the wholesale disruption that has happened with marijuana legalization, public opinion change was necessary, but it was not sufficient. Also required was the disruption of the iron triangle. That was accomplished in the late 2000s through a shrewdly crafted campaign of “asymmetric warfare” that aimed money and argumentation at the incumbent coalition’s weakest points. In particular, reformers shifted the public’s focus from harms of marijuana use to harms of marijuana criminalization.
The rise of commercial marijuana interests and a potentially controversial “marijuana lobby” may impede legalization’s momentum as its opponents change the subject once again, from harms of criminalization to harms of corporate predation.
The present disrupted regulatory environment is unlikely to last. Old prohibitionist interests are discombobulated and new commercial-marijuana interests are still getting organized, giving legalizing states a degree of regulatory freedom which is exceptional but probably not durable. Over time, multiple interests will coalesce and colonize the regulatory process.
Despite widely touted concern that one or more disproportionately powerful players will dominate the regulatory system, regulatory incoherence should be a greater concern than regulatory capture. As policymakers increasingly need to navigate complex and conflicting interest-group politics, the result is at least as likely to be overregulation and misregulation as it is to be systematic underregulation.
June 19, 2016 in Business laws and regulatory issues, History of Alcohol Prohibition and Temperance Movements, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Political perspective on reforms, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
Friday, June 17, 2016
I am not sure when and how we will know for sure that the marijuana industry has gone entirely mainstream, but this new article appearing on the front-page of the New York Times seems like a tipping point moment. The lengthy article, as appearing on-line, is headlined "The First Big Company to Say It’s Serving the Legal Marijuana Trade? Microsoft." (Apparently in the printed paper the headline was "Microsoft Dips Toe Into Trade on Marijuana.") Here are excerpts from the lengthy piece:
As state after state has legalized marijuana in one way or another, big names in corporate America have stayed away entirely. Marijuana, after all, is still illegal, according to the federal government.
But Microsoft is breaking the corporate taboo on pot this week by announcing a partnership to begin offering software that tracks marijuana plants from “seed to sale,” as the pot industry puts it.
The software — a new product in Microsoft’s cloud computing business — is meant to help states that have legalized the medical or recreational use of marijuana keep tabs on sales and commerce, ensuring that they remain in the daylight of legality.
But until now, even that boring part of the pot world was too controversial for mainstream companies. It is apparent now, though, that the legalization train is not slowing down: This fall, at least five states, including the biggest of them all — California — will vote on whether to legalize marijuana for recreational use.
So far, only a handful of smaller banks are willing to offer accounts to companies that grow or sell marijuana, and Microsoft will not be touching that part of the business. But the company’s entry into the government compliance side of the business suggests the beginning of a legitimate infrastructure for an industry that has been growing fast and attracting lots of attention, both good and bad.
“We do think there will be significant growth,” said Kimberly Nelson, the executive director of state and local government solutions at Microsoft. “As the industry is regulated, there will be more transactions, and we believe there will be more sophisticated requirements and tools down the road.”
Microsoft’s baby step into the business came through an announcement on Thursday that it was teaming up with a Los Angeles startup, Kind, that built the software the tech giant will begin marketing. Kind — one of many small companies trying to take the marijuana business mainstream — offers a range of products, including A.T.M.style kiosks that facilitate marijuana sales, working through some of the state-chartered banks that are comfortable with such customers.
Microsoft will not be getting anywhere near these kiosks or the actual plants. Rather, it will be working with Kind’s “government solutions” division, offering software only to state and local governments that are trying to build compliance systems.
But for the young and eager legalized weed industry, Microsoft’s willingness to attach its name to any part of the business is a big step forward. “Nobody has really come out of the closet, if you will,” said Matthew A. Karnes, the founder of Green Wave Advisors, which provides data and analysis of the marijuana business. “It’s very telling that a company of this caliber is taking the risk of coming out and engaging with a company that is focused on the cannabis business.”...
It’s hard to know if other corporate giants have provided their services in more quiet ways to cannabis purveyors. New York State, for instance, has said it is working with Oracle to track medicinal marijuana patients. But there appears to be little precedent for a big company advertising its work in the space. It is still possible — though considered unlikely — that the federal government could decide to crack down on the legalization movement in the states.
The partnership with Kind is yet another bold step for Microsoft as its looks to replace the revenue from its fading desktop software business. On Monday, it announced that it was buying LinkedIn. Microsoft has put a lot of emphasis on its cloud business, Azure. The Kind software will be one of eight pieces of preferred software that Microsoft will offer to users of Azure Government — and the only one related to marijuana.
The conflict between state and federal laws on marijuana has given a somewhat improvisational nature to the cannabis industry. Stores that sell pot have been particularly hobbled by the unwillingness of banks to deal with the money flowing through the industry. Many dispensaries have been forced to rely on cash for all transactions, or looked to startups like Kind, with its kiosks that take payments inside dispensaries.
Governments, too, have generally been relying on smaller startups to help develop technology that can track marijuana plants and sales. A Florida software company, BioTrackTHC, is helping Washington State, New Mexico and Illinois monitor the marijuana trade inside their states....
The opening up of the market in California is already leading to a scramble for the big money that is likely to follow, and Microsoft will now be well placed to get in on the action. Ms. Nelson of Microsoft said that initially her company would be marketing the Kind software at conferences for government employees, but it could eventually also be attending the cannabis events where Kind is already a regular presence. “This is an entirely new field for us,” she said. “We would have to figure out which conference might be the premier conference in this space. That’s not outside the realm of possibility.”
June 17, 2016 in Business laws and regulatory issues, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate, Web/Tech, Who decides | Permalink | Comments (0)
Thursday, June 9, 2016
Notable CDC survey data showing no changes in youth marijuana use despite massive state changes in marijuana law and policy
Via Tom Angell, the founder of Marijuana Majority, I just saw this interesting data report from the Center For Desease Control under the heading "Trends in the Prevalence of Marijuana, Cocaine, and Other Illegal Drug Use, National YRBS: 1991—2015." For those who do not know, the YRBS refers to the nation Youth Risk Behavior Survey which "monitors priority health risk behaviors and "is conducted every two years during the spring semester and provides data representative of 9th through 12th grade students in public and private schools throughout the United States."
The first three lines of data from this link will be of greatest interest to marijuana reform advocate, as it reports from the last 25 years the survey results on the issues of how many high-schoolers have "Ever used marijuana (one or more times during their life)" and have "Tried marijuana before age 13 years (for the first time)" and "Currently used marijuana (one or more times during the 30 days before the survey)." Though I am simplifying the particulars, for all these survey questions, it appears that teen use of marijuana as reported via these surveys generally increased some in the 1990s and generally decreased over the last 15 years. And, of particular note, the CDC report that from 2013 to 2015, these was essentially and statistically speaking "No change." (Also, encouragingly, it appears that use of harder drugs by teens is also either not changing or even "decreasing" in recent years.)
Long story short, while adult use of marijuana is being legalize recreationally in a few states and medically in many more, it appears that so far we are seeing no obvious impact on teen use of marijuana. I am not confident that these trends will persist over a long period of time if marijuana is legalized for recreational use by adults nationwide, but for now there is preliminary data to contradict assertions by opponents that marijuana reform that reform will be leading to significant increases in use by underage populations.
Monday, May 30, 2016
In tradition of George Washington and Thomas Jefferson, Libertarians nominate for Prez a cannabis businessman in Gary Johnson
For a host of reasons, I am pleased to see the Libertarian Party getting more than its usual attention this election cycle; and, as reported here, this past weekend the Libertarian Party selection Gary Johnson and William Weld to be their Prez and VP candidated for 2016. Supporters of marijuana reform likely know the name Gary Johnson, and this recent AP article headlined "This marijuana-loving Libertarian staking claim as Trump alternative," highlights some of the reasons why. Here are excerpts:
Johnson is [going to be] relying on an intensifying schedule of media appearances to boost his name recognition in an effort to reach the necessary 15 percent threshold to qualify for the presidential debates this fall. “We cannot go into a battleground state and compete,” said Johnson’s senior strategist Ron Nielson, citing the high cost of running a campaign in states like Florida or Ohio. The Johnson campaign will instead focus its resources on cheaper states where libertarians have done well in the past, places like Alaska, maybe New Hampshire, he says.
Yet Trump’s Republican critics don’t necessarily need to find a candidate who can win. Many are seeking a legitimate protest candidate where they could focus their anti-Trump energy. Should that candidate earn even a few percentage points in key states this fall, it could hurt Trump’s chances. “Gary will be an outlet for millions of Americans who just can’t fathom the idea of voting for Hillary Clinton or Donald Trump,” said Ed Crane, who co-founded the libertarian-leaning Cato Institute and now runs a super PAC he says may support Johnson “down the road.”...
Johnson represents a set of policies that do not line up perfectly with Republicans or Libertarians. He embraces fiscal conservatism, but not to the lengths that some hardline anti-government libertarians would like. He considers himself a liberal on social issues, supporting same-sex marriage and abortion rights. And he supports a non-interventionalist foreign policy that focuses on America’s challenges at home.
Many know him best for his repeated calls to legalize drugs. Johnson largely focuses his energy on marijuana, but also suggests that concern over narcotics such as heroin are exaggerated compared to the impact of alcohol or even smoking cigarettes. He is a regular marijuana user, noting that he most recently took an edible form of the drug three weeks ago.
“I’m one of the 100 million Americans that do this. If that disqualifies me from being president, so be it,” he told The Associated Press, adding that he recently purchased the drug legally in Colorado but illegally transported it back to his home in New Mexico. “Sure, I’m in the tens of thousands of those that are guilty of that phenomenon,” he says.
He promises not consume marijuana if elected president, however. “I think the American people deserve to know that there will be a steady hand,” he said. “And I would hope that my history regarding this stuff would bear out the fact that I’m a pretty disciplined cat.”
Left out of this story is the fact that Johnson was not so long ago, as reported here, the CEO of Cannabis Sativa Inc. And, as the title of this post is meant to suggest, that history creates a notable connection between Prez Candidate Johnson and our Founders. Specifically, although there is much debate over whether and how the Framers of our Constitution used cannabis, I am pretty sure it is widely acknowledged that both George Washington and Thomas Jefferson grew hemp for sale on their Virginia farms. Thus, like Johnson, they were both involved in cannabis commerce.
May 30, 2016 in Campaigns, elections and public officials concerning reforms, Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Political perspective on reforms, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
Tuesday, May 24, 2016
"As more states legalize marijuana, adolescents' problems with pot decline: Fewer adolescents also report using marijuana"
The title of this post is the headline of this notable Science Daily release that reports on this notable newly published research in the Journal of the American Academy of Child & Adolescent Psychiatry that surely should be getting lots and lots of attention from marijuana reform advocates. Here are the basics via the Science Daily:
A survey of more than 216,000 adolescents from all 50 states indicates the number of teens with marijuana-related problems is declining. Similarly, the rates of marijuana use by young people are falling despite the fact more U.S. states are legalizing or decriminalizing marijuana use and the number of adults using the drug has increased.
Researchers at Washington University School of Medicine in St. Louis examined data on drug use collected from young people, ages 12 to 17, over a 12-year span. They found that the number of adolescents who had problems related to marijuana -- such as becoming dependent on the drug or having trouble in school and in relationships -- declined by 24 percent from 2002 to 2013.
Over the same period, kids, when asked whether they had used pot in the previous 12 months, reported fewer instances of marijuana use in 2013 than their peers had reported in 2002. In all, the rate fell by 10 percent. Those drops were accompanied by reductions in behavioral problems, including fighting, property crimes and selling drugs. The researchers found that the two trends are connected. As kids became less likely to engage in problem behaviors, they also became less likely to have problems with marijuana.
The study's first author, Richard A. Grucza, PhD, an associate professor of psychiatry, explained that those behavioral problems often are signs of childhood psychiatric disorders. "We were surprised to see substantial declines in marijuana use and abuse," he said. "We don't know how legalization is affecting young marijuana users, but it could be that many kids with behavioral problems are more likely to get treatment earlier in childhood, making them less likely to turn to pot during adolescence. But whatever is happening with these behavioral issues, it seems to be outweighing any effects of marijuana decriminalization."
The new study is published in the June issue of the Journal of the American Academy of Child & Adolescent Psychiatry. The data was gathered as part of a confidential, computerized study called the National Survey on Drug Use and Health. It surveys young people from different racial, ethnic and income groups in all 50 states about their drug use, abuse and dependence.
In 2002, just over 16 percent of those 12 to 17 reported using marijuana during the previous year. That number fell to below 14 percent by 2013. Meanwhile, the percentage of young people with marijuana-use disorders declined from around 4 percent to about 3 percent.
At the same time, the number of kids in the study who reported having serious behavior problems -- such as getting into fights, shoplifting, bringing weapons to school or selling drugs -- also declined over the 12-year study period. "Other research shows that psychiatric disorders earlier in childhood are strong predictors of marijuana use later on," Grucza said. "So it's likely that if these disruptive behaviors are recognized earlier in life, we may be able to deliver therapies that will help prevent marijuana problems -- and possibly problems with alcohol and other drugs, too."
Saturday, May 21, 2016
Notable commentary highlights how "Legalized Pot, Free Trade" could significantly improve US-Mexico interactions
This notable new New York Times commentary, authored by Ioan Grillomay and headlined "Legalized Pot, Free Trade," highlights some international benefits that could and should flow from modenr marijuana reform efforts. Here are excerpts:
Speaking last month at the United Nations special session on drugs, President Enrique Peña Nieto said he wanted to relax the nation’s marijuana laws. He has since sent Mexico’s Congress a bill to legalize medicine that contains cannabis, allow people to carry an ounce of marijuana without being prosecuted, and free some prisoners convicted on marijuana charges. “We Mexicans know all too well the range and the defects of prohibitionist and punitive policies, and of the so-called war on drugs that has prevailed for 40 years,” he said.
Mr. Peña Nieto is new to the drug-reform game. Only last year, he said he was against legalizing marijuana, and at one point said he was not even going to attend the United Nations session.
What happened? He seems to have realized (or been advised) that it is better to be on the side of inevitable change. The proposal follows the rapid loosening of drug laws in the United States: Four states and the District of Columbia have legalized medical and recreational marijuana, and 20 more states now permit it as medicine. The president’s shift also follows a November ruling by Mexico’s Supreme Court, which held that the government had no constitutional right to arrest people for their “civil right” of growing cannabis.
And more is coming soon. In November, Californians could vote on an initiative to legalize marijuana. If America’s richest state, and one on the border, votes yes, it will have a huge impact on Mexico. Why would the Mexican government want to crack down on traffickers taking marijuana into California if it were fully legal there?
Various Mexican politicians and activists have come out in favor of wider marijuana legalization. Among them, the opposition senator Mario Delgado has proposed the decriminalization and regulation of cultivation, production and sales across Mexico. The former president Vicente Fox also supports this idea. Mr. Peña Nieto’s proposals make sense, but there’s even more to be done. The current bill would effectively allow cannabis consumption, but it would leave most of the production and selling of it to the black market — which means largely in the hands of drug cartels.
Marijuana reform in the United States has already eaten into the business of Mexican cartels. In 2011, the year before Colorado and Washington State legalized it, the United States border patrol seized 2.5 million pounds of cannabis coming from Mexico. Last year, with marijuana legal in four states and the District of Columbia, that had fallen to 1.5 million pounds.
However, even the latest number indicates that a significant amount of marijuana is still being smuggled north. The profits pay the cartels’ assassins, as well as corrupt police officers and soldiers, who discard piles of bodies across Mexico. Amid these changing dynamics, it becomes more and more pointless for Mexican soldiers (underwritten by the United States, through the Merida Initiative) to keep up the ritual of burning marijuana crops. What is needed, then, is for both countries to move from the current mishmash of laws toward the inevitable conclusion: that marijuana becomes a legalized product that can be traded over borders.
The same market forces that shape the trade in liquor or tobacco will shape the trade in marijuana. Like those, it generates major profits for the formal economy. A research group predicts the legalized marijuana market in the United States will be worth more than $6 billion this year, rising to more than $20 billion by 2020. That could be a boon for the Mexican and United States economies.
A regulated marijuana market won’t suddenly end the bloodshed in Mexico. Cartels would still traffic cocaine, heroin and methamphetamines. The cartels have also diversified to kidnapping, extortion and even oil theft, crimes that can be dealt with only by markedly improved Mexican police forces. But marijuana reform will help immensely. Many in the ranks of Mexican cartels take their first step into the crime world by growing, smuggling or selling pot. That link would be cut, and legal jobs created. Mexican security forces could finally leave the marijuana issue behind to focus on real problems.
The United Nations special session on drugs was heavy on empty talk, but several positive things came out of it. One was that there is no appetite to make countries abide by the United Nations treaties that prohibit the legalization of marijuana. Another is that a range of voices across the world are calling for a new approach to drug policy. The growth of a legalized, binational marijuana market would be a step toward turning those calls into reality.
Tuesday, May 17, 2016
I am a fairly strong proponent of marijuana reforms in large part because there seem to be a number of tangible immediate benefits from legalizating, regulating and taxing the marijuana marketplace, while significant drawbacks rarely prove to be as dire as predicted by opponents of reform. Two new stories in major newspapers today discussing developments in Colorado reinforce my views. Here are headlines, links and exceepts:
From USA Today here, "These kids are going to college on pot":
Colorado pot smokers are helping send 25 students to college, the first scholarships in the U.S. funded with taxes on legal marijuana. The awards offered by Pueblo County, in southern Colorado, are the latest windfall from legal Colorado marijuana sales that are also helping build schools and aid the homeless — and in one county, providing 8% raises to municipal workers.
Pueblo County is granting $1,000 each to the students, with recipients to be announced later this month. “It’s incredible,” said Beverly Duran, the executive director of the Pueblo Hispanic Education Foundation, which is overseeing the scholarships. "Every year we get a nice pool of students … but we can always only award to a small percentage. This for us expands that to extraordinary lengths.”...
Further south in Colorado, Huerfano County expects to collect an extra $500,000 in cannabis taxes this year. That’s bankrolling an 8% raise for almost all of the county's 96 municipal employees, a big deal in an area where a county road worker earns $12 an hour and most employees haven’t had a raise in more than five years....
In Aurora, the state’s third-largest city, marijuana taxes are helping improve roads, pay off a municipal recreation center, and provide direct services for homeless men and women. Aurora has nearly 20 pot shops and five grow sites, generating a projected $5.4 million in new taxes this year.
From the Los Angeles Times here, "Governor who called legalization 'reckless' now says Colorado's pot industry is working":
“The predictions of fire and brimstone have failed to materialize,” said Mason Tvert, spokesman for the Marijuana Policy Project, a national group working to reform pot laws. “Most Coloradoans, including the governor, recognize that the law is working.”
From the start, [Colorado Gov] Hickenlooper saw the legalization of marijuana as a great national experiment, something utterly new in this country and fraught with potential public health and safety issues. He fretted about a potential rise in drug use among children and was clearly uncomfortable with an amendment directly conflicting with federal law, which considers pot an illegal drug on par with cocaine.
There were plenty of snags at first. Marijuana edibles proved especially problematic because few people had experience with them. High-profile overdoses made national news. Just last week a lawsuit was filed against the maker of a marijuana-laced candy, alleging the product triggered a "psychotic episode" that caused a man to kill his wife in 2014. Still, none of Hickenlooper’s worst fears were realized.
Colorado is booming. The state has a 4.2% unemployment rate, one of the best in the country. High-tech companies are moving in. Small towns across the state, some once teetering on the brink of bankruptcy, have been saved by tax revenues from pot dispensaries. And the $1-billion-a-year cannabis business will pump $100 million in taxes into state coffers this year.
Andrew Freedman, director of marijuana coordination for Colorado, said the governor’s views reflect a growing sense of optimism about how the industry is regulated. “In the short run, there have been a lot fewer public safety and health issues than the governor feared in the beginning,” said Freedman, who is often referred to as the state’s marijuana czar. “In the beginning, we had problems with edibles and hash oil fires but now, for the most part, Colorado looks a lot like it did before legalization.”
Marijuana consumption has not changed much from pre-legalization levels and there has been no significant increase in public health and safety problems, he said. As for the $100 million in tax revenue, Freedman noted, that's out of a $27-billion state budget. Some 70% of the money is earmarked for school construction, public health initiatives and other projects. The rest goes back into regulating the industry.
“The governor has called this a grand experiment from the beginning. He looks at data points as he goes along and I think he’s pleasantly surprised that there were not as many challenges as he thought,” Freedman said. “He would say the jury is still out on this experiment but he’s optimistic.”
Some are less circumspect. “The state’s image is actually rising. We were just ranked as the best place to live in America,” Tvert said. “The idea that businesses would not relocate here or conferences wouldn’t be held here was untrue. In fact, attendees at conferences are now offered pot tours as day trips.”
May 17, 2016 in History of Marijuana Laws in the United States, Recreational Marijuana Commentary and Debate, Recreational Marijuana Data and Research, Recreational Marijuana State Laws and Reforms, Taxation information and issues , Who decides | Permalink | Comments (0)
Saturday, May 14, 2016
This new New York Times article, headlined "How Much Is Too Much Marijuana to Drive? Lawmakers Wonder," not only picks up on the recent AAA reports on marijuana impairment and driving, but also spotlights how federal law continues to get in the way of needed research on these issues:
As more states consider legalizing the substance, that presents a challenge to legislators seeking to create laws on driving while impaired by marijuana.
The study, commissioned by the AAA Foundation for Traffic Safety, found that laws in six states that legally assess impairment by measuring how much THC (the active ingredient in marijuana) is in a person’s blood are not supported by science. “There is no concentration of the drug that allows us to reliably predict that someone is impaired behind the wheel in the way that we can with alcohol,” said Jake Nelson, AAA’s director of traffic safety advocacy and research....
The AAA study echoes the recommendations of many experts who call for the improvement of technology to evaluate drivers’ saliva for cannabis use.
Sean O’Connor, the faculty director of the Cannabis Law and Policy Project at the University of Washington, said that there was promising research into detecting cannabis through saliva and other techniques, but that it was being stymied by the drug’s legal classification as a Schedule 1 substance. “We are hamstrung by the fact that you can’t do legitimate scientific research unless you have a Schedule 1 license,” he said. His argument underlines the difficulty for states trying to write coherent policy when the drug is still illegal under federal law.
Prior recent related post:
Friday, May 13, 2016
Earlier this week, I had the great honor and pleasure of talking with Jeffrey Rosen and Randy Barnett as part of the National Constitution Center's "We the People" series concerning various constitutional issues related to the regulation and legalization of marijuana. The podcast is available at this link, and here is how it is introduced via that webpage:
Marijuana was first outlawed nationally by the Marijuana Tax Act in 1937. Since 1970, it has been classified an illegal Schedule 1 drug under the Controlled Substances Act, listed alongside LSD, heroin, and other narcotics.
But in 1996, California became the first state to allow the use of marijuana for medical purposes, starting a cascade of changes at the state level. As of May 2016, 24 states and D.C. have legalized medical marijuana; four states — Colorado, Washington, Oregon, Alaska—and D.C. have also legalized recreational marijuana. In November 2016, more states, including Nevada and Maine, are slated to vote on the issue.
Join We the People to explore the constitutional issues at stake....
May 13, 2016 in Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (0)
Thursday, May 12, 2016
Marijuana sales and tax revenues keep going up and up in Colorado ... while tangible new serious problems seem still not to have (yet?) materialized
This new Denver Post piece, headlined "Colorado pot shops have already sold $270 million of marijuana in 2016," reports that "in the first three months of 2016, Colorado's pot shops sold more than $270 million of marijuana and related products." Here is more:
The state’s latest data shows that its marijuana shops sold nearly $90 million of cannabis in March 2016. The licensed stores sold more than $55 million in recreational marijuana and more than $33 million in medical cannabis in March, the latest month for which the department has released tax data for the industry. Totals for retail and medical marijuana dipped slightly in March after a bustling February, which was the state’s fifth most lucrative month for sales since they began in January 2014, according to Cannabist calculations and state data.
March 2016 totals for recreational pot sales are up 30 percent from March 2015, which shows that “marijuana sales remain strong,” said Christian Sederberg, an attorney for the cannabis industry. “As the regulated system continues to work, we’re also on pace to have over $40 million in excise taxes, meaning there could be additional taxes available from the excise tax to be used for something beyond the public school construction fund.”
Among the taxes collected on retail pot sales is the school-funding 15 percent excise tax on wholesale marijuana transfers, which amounted to $3.5 million in March. One of the cornerstones of the campaign that successfully ran Colorado’s pot-legalizing Amendment 64 says that the first $40 million raised by that excise tax will go toward school construction projects. That specific tax totaled $13.3 million in 2014 and $35 million in 2015, and industry analysts — Sederberg included — say they are confident it will top $40 million in 2016.
Colorado marijuana outlets sold more than $699 million of product in 2014 and more than $996 million in 2015. Year-over-year totals for taxes and license fees grew too, from $76 million in 2014 to $135 million in 2015. There are three types of state taxes on recreational marijuana: the standard 2.9 percent sales tax; a 10 percent special marijuana sales tax; and a 15 percent excise tax on wholesale marijuana transfers. For March, Colorado collected more than $11.3 million in recreational taxes and fees and more than $1.7 million in medical taxes and fees.
Intriguingly, this notable new Atlantic piece, headlined "The Failed Promise of Legal Pot: New laws on marijuana were supposed to boost tax revenues and free up cops to go after “real” criminals. But underground sales — and arrests — are still thriving," details that marijuana legalization in Colorado and other states has not yet completely eliminated the historic black-market realities of marijuana distribution. Though I find useful this article's reminder that, even after legalization, there can be many persistent black market and prohibition problems, I also think the article highights reasons why we may expect marijuana sales and tax revenues to keep on increasing over time as more and more local marijuana consumers come to prefer engaging with the newer-and-always-innovating legal market over their older-and-surely-less-dynamic black market.
In addition to noting these sales and tax revenue trends, the headline of my post here is meant to flag the reality that we do not seem to have yet seen evidence of increasing serious new problems in Colorado to parallel the evidence of increasing sales and tax revenue. If there were significant tangible short-terms harms that follow directly from legalizing recreational marijuana and having robust retail sales, I think those harm would now start to become very obvious now nearly 45 months since Colorado voters enacted full legalization and 30 months into having retail outlets selling lots of this product. Moreover, if there were significant tangible short-terms harms that follow directly from legalizing recreational marijuana, not only should they be evident by now, but they should be contining to grow and become even more evidence as legal sales continue to increase.
Critically, it is certainly possible that there are significant long-term harms for Colorado and elsewhere that can be linked directly to marijuana legalization and increasing legal sales, especially with respect to health concerns. (The parallel here to tobacco should be clear: having lots of people smoke lots of cigarettes does not produce a lot of obvious short-term harms, but the long-term harms we now know are quite significant.) But if sales and tax revenues keep going up and evidence of major problems are not yet materializing, it is going to be difficult to effectively campaign in other states against marijuana reform when the tangible cost-benefit realities in Colorado so far seem pretty darn good.
May 12, 2016 in History of Marijuana Laws in the United States, Recreational Marijuana Data and Research, Recreational Marijuana State Laws and Reforms, Taxation information and issues | Permalink | Comments (0)
Wednesday, April 27, 2016
The Room for Debate section of the New York Times yesterday had an interesting quartet of pieces discussing marijuana reform focused on the "gateway drug" notion. Here is the section's introductory set up:
The drive to marijuana legalization has grown more powerful as the crisis of heroin and opioid addiction has become more troubling. Now some officials say efforts to legalize marijuana should stop because, they say, greater availability would increase use and marijuana can be a gateway to the use of other drugs.
But is marijuana a gateway drug and, for that reason, should it remain illegal?
Here are the contribututions, with links via the commentary titles and the brief summaries provided by the Times:
Robert L. DuPont, "Marijuana Has Proven to Be a Gateway Drug": Establishing it as a third legal drug, along with tobacco and alcohol, will increase drug abuse, including the expanding opioid epidemic.
Colleen L. Barry, "Overdoses Fell with Medical Marijuana Legalization": Medical marijuana might be safer for chronic pain management than opioids but more research is needed.
Ethan Nadelmann, "Fears of a Gateway Effect Vastly Exceed the Evidence": The vast majority of people who use marijuana never progress to using other illicit drugs, or even to becoming regular marijuana consumers.
Deborah Peterson Small, "Look at the Real Gateways to Addiction": Many promote myths about marijuana to justify the use of law enforcement and the testing of people for public benefits, jobs and exclusion from housing.
Monday, April 18, 2016
This new Denver Post piece, headlined "Fewer Coloradans seek treatment for pot use, but heavier use seen," reports on this notable new official state government report from Colorado (which I believe was just released today, but bears a cover date of March 2016). Here is a basic summary via the Denver Post piece:
Colorado's treatment centers have seen a trend toward heavier marijuana use among patients in the years after the state legalized the drug, according to a new report from the Colorado Department of Public Safety. The 143-page report released Monday is the state's first comprehensive attempt at measuring and tracking the consequences of legalization.
In 2014, more than a third of patients in treatment reported near-daily use of marijuana, according to the report. In 2007, less than a quarter of patients reported such frequency of use. Overall, though, the number of people seeking treatment for marijuana has dropped since Colorado voters made it legal to use and possess small amounts of marijuana. The decrease is likely due to fewer people being court ordered to undergo treatment as part of a conviction for a marijuana-related crime.
The finding is among a growing body of evidence that marijuana legalization has led to a shift in use patterns for at least some marijuana consumers. And that is just one insight from the new report, which looks at everything from tax revenue to impacts on public health to effects on youth. Among its findings is a steady increase in marijuana use in Colorado since 2006, well before the late-2000s boom in medical marijuana dispensaries. The report documents a sharp rise in emergency room visits related to marijuana. It notes a dramatic decline in arrests or citations for marijuana-related crimes, though there remains a racial disparity in arrest rates.
But the report, which was written by statistical analyst Jack Reed, also isn't meant as a final statement on legalization's impact. Because Colorado's data-tracking efforts have been so haphazard in the past, the report is more of a starting point. "[I]t is too early to draw any conclusions about the potential effects of marijuana legalization or commercialization on public safety, public health, or youth outcomes," Reed writes, "and this may always be difficult due to the lack of historical data."
It's not just the lack of data from past years that complicates the report. Reed also notes that legalization may have changed people's willingness to admit to marijuana use — leading to what appear to be jumps in use or hospital visits that are really just increases in truth-telling. State and local agencies are also still struggling to standardize their marijuana data-collection systems. For instance, Reed's original report noted an explosive increase in marijuana arrests and citations in Denver, up 404 percent from 2012 to 2014. That increase, however, was due to inconsistent data reporting by Denver in the official numbers given to the state.
Intriguingly, though this lengthy report comes from the Colorado Department of Public Safety, not very much of the report discusses general crimes rates at much length. But what is reported in this report is generally encouraging:
Colorado’s property crime rate decreased 3%, from 2,580 (per 100,000 population) in 2009 to 2,503 in 2014.
Colorado’s violent crime rate decreased 6%, from 327 (per 100,000 population) in 2009 to 306 in 2014.
April 18, 2016 in History of Marijuana Laws in the United States, Initiative reforms in states, Medical Marijuana Data and Research, Recreational Marijuana Data and Research, Taxation information and issues | Permalink | Comments (0)
Sunday, April 17, 2016
Cannabis Science and Policy Summit: on-site reporting from the Vicente Sederberg Professor of Marijuana Law and Policy
I invited Sam Kamin, the Vicente Sederberg Professor of Marijuana Law and Policy at the University of Denver Sturm College of Law, to provide some reports or thoughts about his experiences today and tomorrow as he is participating in NYC at the The Cannabis Science and Policy Summit. Here is the first of what I hope might be a few on-site report from a very informed participant in this event:
The morning started with a cautionary tone. Jonathan Caulkins gave a plenary talk on the dangers of a profit-driven marijuana market. His thesis was that 25 years from now, policy makers will look back on this period and wonder what on earth we were thinking.
* He showed that half of marijuana is consumed by those who use daily and that, as with any industry, there will be a push from industry to grow that group.
* He argued that Americans spend 40 billion hours per year stoned and that we could easily expect that to double post-legalization.
* He called marijuana a performance-degrading drug. There's a reason we don't test chess players for pot to be sure they're not cheating.
In the questions and discussions in the hallway afterward, talk focused on possible alternatives to a market-driven legal market. The most concrete was David Courtwright's invocation of Sweden's Gothenburg public house regulatory system (limited number of licenses, a limit on maximum profits, etc.) as a model for marijuana regulation that minimizes social harm.
A fascinating (to me) issue is whether there is room for legalization's opponents (groups like SAM and policy wonks like Caulkins) and the cannabis true believers who started all this (DPA, MPP, NORML, etc.) to join forces against Big Marijuana. Talking to Dan Riffle, I compared this to the Never Trump movement. No one (except the eventual winners, whoever they will be) wants corporate marijuana, which looks like the front-runner at the moment. The question will be whether various opponents, coming at that place from different directions, can find sufficient common ground to organize against the juggernaut and whether they can do so before things become inevitable.
For the record and to be a bit of an iconoclast, I consider myself something of a supporter of "corporate marijuana" at least in the short term for a couple of reasons. First and foremost, in the arena of medical marijuana, I think we will only get lots and lots of needed dynamic and aggressive research on the potential of the cannabis plant if there is a significant profit motive driving the research. Second and not to be overlooked, I think there can and should be more external benefits (like job growth and tax revenue) flowing from a commercial marijuana marketplace if (and this is a big if) government if focused mostly on aggressively regulating the marijuana industry rather than excessively seeking to control/hamper its innovative tendencies.
Friday, April 15, 2016
"Marijuana Could Soon Be Rescheduled As A Less Dangerous Drug By The DEA, So Why Aren’t Cannabis Proponents Excited?"
The title of this post is the headline of this astute new International Business Times article, and here are exerpts:
After decades of intransigence on the issue, the Drug Enforcement Administration may finally recommend removing marijuana from the list of the country’s most dangerous drugs. That list was created as part of the Controlled Substances Act (CSA) of 1970, which consolidated all federal drug laws into a single comprehensive measure and defined marijuana as a Schedule I controlled substance, alongside heroin, LSD and other drugs that the government says have no medical value and the highest potential for abuse. That meant marijuana was saddled with the strictest possible restrictions and penalties.
Ever since then, marijuana activists have been fighting to remove cannabis from that category. In 1972, the National Organization for the Reform of Marijuana Laws (NORML) petitioned the DEA to instead place marijuana in Schedule II of the CSA, alongside cocaine, meth and other drugs considered dangerous but with medical potential. Twenty-two years and multiple courtroom battles later, the DEA had a final decision: Marijuana would remain a Schedule I substance.
The DEA has rejected two other marijuana rescheduling petitions since then, but now there’s a glimmer of hope among activists that change could finally be in the works. As first reported last week by the Huffington Post, in a recent letter to a group of Democratic senators, the DEA referenced a 2011 petition to reschedule cannabis to Schedule II, noting, “DEA understands the widespread interest in the prompt resolution to these petitions and hopes to release its determination in the first half of 2016.” While there’s a good chance this determination will be no different than in the past, the country’s rapidly shifting cannabis landscape — with 23 states plus Washington, D.C., having legalized medical marijuana (and Pennsylvania poised to do so) — makes some people think the DEA could be ready to concede that cannabis has medicinal value.
But instead of being cause for celebration, the news has met with largely subdued reaction from marijuana activists and business owners. “Symbolically, one could say that would be a victory because you’d have for the first time the federal government acknowledging that cannabis does in fact have some therapeutic utility,” said NORML deputy director Paul Armentano. “But that by and large would be the extent of it. By moving marijuana from Schedule I to II, the federal government would still be putting forward the intellectual dishonesty that cannabis has a high potential for abuse and needs to be regulated accordingly.”
Such responses suggest it’s not just the DEA that’s shifting its position on federal marijuana laws. Marijuana proponents’ stance on federal cannabis rules are evolving, too. As the movement racks up one legal victory after another with little federal acknowledgement, there’s a growing belief that the cannabis crusade doesn’t have to settle for marijuana's move to Schedule II, for which it has long lobbied. Some even worry that such a rescheduling could in fact limit or derail a thriving industry.
A handful of drugs have been rescheduled like this before. Marinol, a synthetic version of marijuana’s psychoactive components, was moved from Schedule I to Schedule II, and then to Schedule III in the 1980s and '90s. But rescheduling is rare. According to John Hudak, deputy director of the Brookings Institution’s Center for Effective Public Management, the DEA has rescheduled substances 39 times since the CSA was ratified 46 years ago, and only five of those instances involved moving a drug from Schedule I to II. Many drug policy experts aren’t optimistic that marijuana will soon be the sixth instance of this happening. After all, the DEA bases such decisions on existing marijuana research — research that has long been severely limited thanks in part to restrictions related to marijuana’s Schedule I status. Even if the DEA recommends rescheduling marijuana in the next few months, the change wouldn’t happen overnight; it would instead trigger a lengthy rulemaking process. “Even if the DEA comes out in July and says, ‘We are moving from I to II,’ it would still take about a year for that to happen,” said Hudak.
But if rescheduling does occur, some marijuana activists say there would be major repercussions. By acknowledging marijuana has medical use and placing it in the same category not just as cocaine but also Vicodin and Ritalin, the government would be signaling that times have changed. “This stands to be a legacy-defining move for Obama if his administration makes the right decision here,” said Tom Angell, founder of the cannabis advocacy group Marijuana Majority. “It would send a strong message to states that do not yet have medical marijuana laws on the books and a strong message to governments around the world that the U.S. government is now on board [with marijuana policy reform].”
The move wouldn’t just be symbolic. Moving marijuana to Schedule II would remove some of the logistical hurdles and academic taboos limiting cannabis research. It would also eliminate several of the bureaucratic hassles plaguing marijuana markets around the country because of the drug’s Schedule I status, such as confusion over whether publications with marijuana ads can be sent through the mail.
But as many marijuana supporters point out, shifting cannabis to Schedule II would not solve the biggest problems facing the nascent marijuana industry. Many unique barriers for marijuana research would still remain, such as the fact that all cannabis for such studies has to be obtained, via a lengthy and complicated approval process, from a single marijuana grow at the University of Mississippi that’s administered by the National Institute on Drug Abuse (NIDA). “The big issue is Ole Miss’ marijuana monopoly, and this wouldn’t fix that at all,” said drug-policy expert Mark Kleiman, a professor of public policy at the New York University Marron Institute of Urban Management.
Then there’s the fact that the biggest headaches afflicting marijuana businesses, such as a lack of banking services and sky-high tax rates thanks to IRS section 280E, which prohibits drug dealers from deducting the costs of selling illicit substances, are due to laws that cover drugs in both Schedules I and II of the CSA. “Moving it to Schedule II really doesn’t accomplish a lot, and frankly it is not scientifically supportable,” said Taylor West, deputy director of the National Cannabis Industry Association. “From a business perspective, it is unclear [if] it would have any impact on the banking situation, and it is specifically clear it would not have any impact on the 280E situation.”
Some marijuana advocates go further, worrying moving marijuana to Schedule II could actually make things worse. Could rescheduling open the door to Big Pharma moving in and taking over the industry? Or could it force all marijuana to be sold by prescription in pharmacies, doing away with the dispensary and recreational marijuana shop markets spreading across the country? “I think a risk that this creates is that it enables DEA to become more directly involved in the control of the current medical cannabis industry,” said Eric Sterling, executive director of the Criminal Justice Policy Foundation. “And that many of the features of the current medical cannabis industry that the public appreciates and values could be lost or destroyed. The DEA would be able to write regulations of the production and processing and distribution of medical cannabis, and they could be quite onerous.”
Others believe such fears are unfounded. “I think if Big Pharma really wanted marijuana to be a huge part of its product line, you would have seen it push the government long ago to consider rescheduling,” said Hudak at the Brookings Institution. Hudak also doesn’t expect to see the federal government dismantling the current marijuana industry: “The state systems are so large, economically and in terms of the people who are served, and they have become entrenched. And frankly, it would be a tremendous enforcement action by the U.S. government to shut them all down, and it would likely be beyond the enforcement resources of the U.S. government right now.”
April 15, 2016 in Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Medical Marijuana Commentary and Debate, Medical Marijuana Data and Research, Who decides | Permalink | Comments (0)
Tuesday, April 12, 2016
Looking critically at the disproportionate impact that drug trafficking laws have on women (with emphasis on race, motherhood, and socioeconomic class)
The impact of the drug war on particular individuals and communities is a focal point for a student presentation this week in my semester-long OSU Moritz College of Law seminar on marijuana reform. My student provided this summary blurb to go along with the following links to background reading:
Between 1980 and 2010, the number of women in prison increased by 646 percent. And of those women, approximately 65 percent incarcerated in state prisons have a minor child; in comparison 55 percent of males in prison report having a minor child. My presentation will focus on the disproportionate impact that drug trafficking and conspiracy laws have on women, with emphasis on race, motherhood, and socioeconomic class. The discussion will be centered around the history of the war on drugs, incarceration trends of women, drug laws, and the familial consequences of incarceration.
Please read the following articles:
Thursday, April 7, 2016
The title of this post is the headline of this valuable new piece by Jacob Sullum at Reason which provides some needed context (and justified pessimism) in light of some press headlines suggesting DEA may be on the verge of reclassifying marijuana. Here is how the piece starts and ends and its main insights in between (with links from the original):
In a memo it sent to members of Congress on Monday, the Drug Enforcement Administration (DEA) says it hopes to announce by the end of June whether it has decided that marijuana no longer belongs in Schedule I of the Controlled Substances Act (CSA), the law's most restrictive category. The memo, first noted yesterday by Washington Post drug policy blogger Christopher Ingraham, has generated headlines such as "The DEA Will Soon Decide Whether it Will Reschedule Marijuana" and "DEA May Downgrade Marijuana From Schedule 1 Drug." Here are three reasons I think those headlines are misleading:1. The DEA has a history of foot dragging in response to rescheduling petitions. This is the fourth time the DEA has responded to a petition asking it to reclassify marijuana. It rejected the first three petitions from six to 16 years after they were filed. The fourth petition, filed in 2009 by New Mexico medical marijuana activist Bryan Krumm, and the fifth petition, filed in 2011 by Christine Gregoire, then the governor of Washington, and Lincoln Chafee, then the governor of Rhode Island, are still pending....
2. Agreeing to reschedule marijuana would require a major change in how the DEA interprets the CSA. Schedule I is supposedly reserved for drugs with a high abuse potential that have "no currently accepted medical use" and cannot be used safely, even under a doctor's supervision. It is doubtful that marijuana meets any of those criteria, let alone all three. But the DEA has always insisted that marijuana cannot be moved until its medical usefulness has been confirmed by the kind of expensive, large-scale clinical studies that the Food and Drug Administration demands before approving a new medicine. While such studies have been conducted with marijuana's main active ingredient (which is how Marinol, a capsule containing synthetic THC, was approved by the FDA in 1985), they have not been conducted with the whole plant....
3. The Obama administration says marijuana will be reclassified only if Congress decides to do so. "What is and isn't a Schedule I narcotic is a job for Congress," President Obama told CNN's Jake Tapper in 2014. "It's not something by ourselves that we start changing." Last January, White House Press Secretary Josh Earnest reiterated that Obama had no interest in administratively rescheduling marijuana: "There are some in the Democratic Party who have urged the president to take this kind of action. The president's response was, 'If you feel so strongly about it, and you believe there is so much public support for what it is that you're advocating, then why don't you pass legislation about it, and we'll see what happens.'"
Eric Holder, Obama's attorney general until last year — and therefore the official directly charged with deciding how controlled substances should be classified, a task that he, like his predecessors, delegated to the DEA — took the same line. Even when Holder said, 10 months after leaving the Justice Department, that marijuana "ought to be rescheduled," he added that "Congress needs to do that."
Although Gary Johnson is optimistic that the administration will change course this year, I see no reason to think the DEA's answer to the two most recent rescheduling petitions will be any different from its answer to the first three.
Wednesday, April 6, 2016
The question in the title of this post is the query to be explored by an LL.M. student in my seminar this week. Here are the suggested background readings and materials she provided to set up this important topic:
Is the legalization of marijuana a better solution than a war on drugs?
My presentation focuses on the impact that the legalization of marijuana in the US is having in Mexico which is the biggest supplier of marijuana. Also, if the legalization of marijuana is a better solution that the drug war and how the US is supporting Mexico on this drug war. These are the articles I recommend my classmates to read:
April 6, 2016 in History of Marijuana Laws in the United States, International Marijuana Laws and Policies, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate | Permalink | Comments (0)
Tuesday, April 5, 2016
As students in my semester-long OSU Moritz College of Law seminar on marijuana laws and reform continue assembling readings on particular topics in preparation for an in-class presentation/discussion, this week we have a student taking a deep dive into marijuana propaganda past and present. Here are links to assembled resources and his summaries:
This article provides a good timeline of early Marijuana propaganda and identifies some of the common themes underlying public marijuana education through the 1950s. It also discusses the themes of racism underlying early marijuana advertising.
Identifying the changing themes of government propaganda over the years. Beginning with violent crime, shifting to laziness, health concerns, gateway drugs, and eventually focusing on youth access to marijuana in the modern day. This article showcases the ways that government sponsored marijuana education has changed over the years as public perception of the drug also changes.
A Pew Research study showcasing attitudes towards marijuana based on age. A correlation can be drawn between reasons that a certain age group opposes legalization and the messages presented during their time. The Silent Generation who was coming of age during Reefer Madness opposes legalization because of the perceived violent nature of marijuana, while members of Gen X oppose legalization because of the perceived health risks presented by marijuana. A relation to their exposure to the “Your Brain on Drugs” campaign during the ‘80s.
Finally, a video I edited to try and capture the essential themes and messages presented in both Reefer Madness and Ten Nights in a Bar Room. The two films have been edited down to try and present only the biggest anti-marijuana/alcohol themes in the movies. If fellow classmates would like a brief introduction to what marijuana education looked like in the ‘30s I would hope this properly captures and showcases the political climate at the time.
April 5, 2016 in Assembled readings on specific topics, History of Alcohol Prohibition and Temperance Movements, History of Marijuana Laws in the United States, Recreational Marijuana Commentary and Debate | Permalink | Comments (0)
The question in the title of this post is the query that defines the work of one of my seminar students who will be presenting on this topic to the rest of the class this week. Here is his suggested background readings and materials to set up this important topic:
General Overview Material
Background on "Big Tobacco" Regulation
FDA v Brown and Williamson, 529 U.S. 120 (2000).
First Amendment / Online Marijuana Advertising/ Commercial Speech Doctrine
Brown v Entertainment Merchants Assn., 564 U.S. ___ (2011).
Marijuana Perspective on Video Game Advertising targeted toward Marijuana Users
April 5, 2016 in Assembled readings on specific topics, Business laws and regulatory issues, History of Marijuana Laws in the United States, Recreational Marijuana Commentary and Debate | Permalink | Comments (0)
Wednesday, March 30, 2016
The title of this post is the notable headline of this notable Vanity Fair article, which serves as a very fitting follow-up to my students' recent class presentation on Women & Weed: Blazing A Trail Toward Nationwide Legalization. Here are the details:
Whoopi Goldberg has had it with cramps and had it with stoner jokes, and now she’s doing something about both. Goldberg announced Wednesday that she’s launching a medical-marijuana company with Maya Elisabeth, one of the leading “canna-businesswomen” in the field, with a line of products designed to provide relief from menstrual cramps.
The company, Maya & Whoopi, will offer cannabis edibles, tinctures, topical rubs, and a THC-infused bath soak that it describes as “profoundly relaxing.” Frankly that last one, even though your humble reporter is a man, sounds incredible.
In an interview with Vanity Fair, The View co-host said she wanted to create a product for women that was discreet, provided relief, and wouldn’t leave you glued to your couch. “For me, I feel like if you don’t want to get high high, this is a product specifically just to get rid of discomfort,” she says. “Smoking a joint is fine, but most people can’t smoke a joint and go to work.”
“This, you can put it in your purse,” Goldberg continues. “You can put the rub on your lower stomach and lower back at work, and then when you get home you can get in the tub for a soak or make tea, and it allows you to continue to work throughout the day.”
Goldberg has been outspoken about her medical-marijuana use in the past. In 2014, she wrote in The Cannabist about her love of her kush-filled vape pen, which she says gives her relief from glaucoma-related headaches without resorting to eating handfuls of Advil every day . “I started using the vape pen because I stopped smoking cigarettes about four years ago and discovered I couldn’t smoke a joint anymore,” she says. “The relief that I got with the vape pen was kind of different from what I got with smoking. I could control it much better.”
If it worked so well for headaches, surely it could be applied to other aches, so Goldberg got in touch with a couple of industry experts to see if there was already anything on the medical-marijuana market for cramps. They told her no, because it was seen as a niche. At this point in the interview, Goldberg stops to give an exasperated chuckle. “Hey, this niche is half the population on the earth,” she says. “This seems to be people flippantly blowing you off, which is what you get whenever you start talking about cramps. They weren’t thinking how do you target this? I have grown granddaughters who have severe cramps, so I said this is what I want to work on.”
Goldberg then got in touch with Elisabeth, the owner of the female-run medical-marijuana cannabis company Om Edibles in northern California, and the two were off to the races.... Goldberg stands by her product for the same reason she favors it over painkillers for headaches. She says you’ll be able to look at the ingredients on any Whoopi & Maya package and know exactly what’s in it. (Queen Victoria, by the way, supposedly used a marijuana tincture to relieve menstrual cramps, so it basically has the seal of approval from the British royalty.)
For those who don’t have much experience in the field, Whoopi & Maya will also include products with only cannabidiol (CBD), which lacks the euphoric effects commonly associated with marijuana. The whole line is scheduled to be available in April. For now, thanks to the patchwork of state medical-marijuana laws and the continuing federal ban on the substance, it will only be available in California.